Xencor is a biopharmaceutical company that develops engineered antibody therapeutics for cancer and autoimmune diseases using its proprietary XmAb Fc domain engineering platform, which enables the design of bispecific and trispecific antibodies with enhanced immune activity, extended half-life, and multi-target mechanisms of action. The company advances these candidates through clinical development as wholly owned programs while also generating revenue through partnerships with major pharmaceutical companies—including Incyte, Alexion, Amgen, Astellas, and Janssen—via upfront payments, regulatory and sales milestone payments, and royalties on commercialized products. Three medicines developed using Xencor's XmAb technologies have already reached market, validating the utility of its modular protein engineering platform across oncology and autoimmune indications.